Novartis Key Multiple Sclerosis Product Gilenya Gets Approval In China
Novartis Is Reimagining Medicine To Improve And Extend People'S Lives. As A Leading Global Medicines Company, It Use Innovative Science And Digital Technologies To Create Transformative Treatments In Areas Of Great Medical Need.Multiple Sclerosis (Ms) Is Categorized As Rare Disease In China With An Estimated 30,000 Ms Patients In China. Gilenya Is The 3Rd Most Prescribed Ms Disease Modifying Treatment Worldwide. Today, Gilenya Is Widely Recognized By Doctors With Over 283,000 Patients Treated With Gilenya To Date.Novartis Is Committed To Bringing Innovation To China And To Reimagining Care For Patients. Entresto
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
